Apimeds Pharmaceuticals US (APUS) is planning to raise $20 million in an initial public offering on the week of February 24th, IPO Scoop reports. The company will be issuing 4,500,000 shares at $4 ...

Dublin, Feb. 25, 2025 (GLOBE NEWSWIRE) -- The "USA Pharmaceutical Directory 2025" has been added to ResearchAndMarkets.com's offering. The USA Pharmaceutical Directory is one of the most ...

Apimeds Pharmaceuticals US, Inc. (APUS) expects to raise $20 million in an initial public offering (IPO) on Friday, February 21st, IPO Scoop reports. The company will issue 4,500,000 shares at $4. ...

Senores Pharmaceuticals Limited announced the acquisition of US marketing rights for Roflumilast tablets through its American subsidiary. The deal with Breckenridge Pharmaceutical, Inc., ...

Two of the most notable examples of this in recent years are Actavis ... US firm choosing to launch its first-in-class cystic fibrosis drug Kalydeco around the world without a big pharma partner.

Dublin, Feb. 25, 2025 (GLOBE NEWSWIRE) -- The "USA Pharmaceutical Directory 2025" has been added to ResearchAndMarkets.com's offering. The USA Pharmaceutical Directory is one of the most comprehensive ...

Apimeds Pharmaceuticals US, Inc. is a clinical stage biopharmaceutical company that is in the process of developing Apitox, a proprietary intradermally administered bee venom-based toxin ...

Any potential US tariffs on Indian pharmaceutical exports could primarily affect American consumers, as stated by Pharmexcil. With India sending over USD 8 billion worth of generic drugs annually, ...

“Share five things you did for Tesla shareholders this week…”: Elon Musk questioned by Tesla shareholders as stock declines for sixth consecutive session Tesla shareholders are growing ...

BLCO may be sold in 2025 to service the debt of majority shareholder BHC, and any sale will be at a premium to the current ...